



CABENUVA

cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
extended-release injectable suspensions

Alternative Sites for Administration: An Overview



An Alternative Site for Administration (ASA) is a facility, other than the prescribing physician's office, that may provide a flexible option for the administration of CABENUVA injections.

ViiVConnect may provide ASA options for your patients to receive CABENUVA injections

If you prefer that CABENUVA injections be administered outside of your office setting, an ASA may be an appropriate option for you and your patients

Have an ASA in mind for your patient?

Need help identifying an ASA for your patient?*

Complete the CABENUVA Enrollment Form

In section 5 ("Injections Will Be Administered at"):

- Check "at the following" and enter the facility information

In section 5 ("Injections Will Be Administered at"):

- Check "unknown"

Once you submit the CABENUVA Enrollment Form, ViiVConnect will:

1. Conduct a benefits verification
2. Confirm that the facility chosen is in-network, based on the patient's insurance

1. Conduct a benefits verification
2. Provide up to 3 in-network ASAs for your patient on the Summary of Benefits

The CABENUVA ASA Locator Tool may help you and your patients find a local Alternative Site for Administration*

Please visit
viiivconnect.com/ASALocator

OR



Please scan
QR code to find an ASA



Is your facility interested in becoming an Alternative Site for Administration?

If your facility is interested in administering CABENUVA and would like to be listed on the CABENUVA ASA Locator Tool, please download and complete the ASA Locator Agreement Form at viiivconnect.com/injectable/asa-locator/ and submit it to ViiVConnect.

For additional information about ASAs,
contact your Territory Account Manager

*The CABENUVA ASA Locator Tool may show potential ASA locations, and ViiVConnect can verify patient benefits at a specific location.



Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
©2021 ViiV Healthcare or licensor.
CBROGM210002 January 2021 Produced in USA.



CABENUVA
cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
extended-release injectable suspensions